Want to join the conversation?
British pharmaceutical group $GSK said it would buy the portfolio of experimental HIV drugs from its U.S. rival $BMY for a total of $1.46Bil in two transactions. $GSK expects to complete both the transactions during the first half of FY16. The deal is expected to strengthen $GSK's global HIV business ViiV Healthcare's control in the HIV market.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.